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Abstract
Amaç: Bu çalışmada, allogeneik hematopoetik kök hücre nakli 
(HKHN) geçiren akut myeloid lösemi (AML) hastalarında NPM1 ve 
FLT3 mutasyonlarının varlığında, DNMT3A ekzon 23 mutasyonlarının 
prognostik etkilerinin değerlendirmesi amaçlanmaktadır.
Gereç ve Yöntemler: Bu çalışma Shariati Hastanesi Hematoloji-
Onkoloji ve Kök Hücre Araştırma Merkezi’ne başvuran 128 erişkin AML 
hastasını kapsamaktadır. NPM1 ve FLT3-ITD mutasyonları, fragman 
analizi ile tespit edilmiştir. DNMT3A ekzon 23 mutasyon analizi için 
Sanger dizi analizi kullanılmıştır. Genel sağkalım (OS) ve relapsız 
sağkalım (RFS) eğrileri için Kaplan-Meier yöntemi ve gruplar arası 
farklılıkları hesaplamak için log-rank testi kullanılmıştır.
Bulgular: DNMT3A ekzon 23 mutasyonlarının prevalansı %15,6 olarak 
bulunmuştur ve bunların içinde sıcak bölge R882 mutasyonları öne 
çıkmaktadır. Tek değişkenli analiz kullanılarak DNMT3A ekzon 23 
mutasyonları olan ve olmayan hastalarda RFS ve OS karşılaştırılmış ve 
bu hasta grupları arasında anlamlı fark bulunmamıştır. Aksine, FLT3-
ITD mutasyonu taşıyan ve allogeneik HKHN geçiren AML hastalarında 
OS (p=0,009) ve RFS (p=0,006) değerleri anlamlı derecede düşmüş 
olarak gözlenmiştir. Bir sonraki adımda, AML hastaları FLT3-ITD ve 
DNMT3A mutasyonları açısından dört gruba ayrılmıştır ve DNMT3A 
R882mut/FLT3-ITD mutasyonu taşıyan hastalar en kötü OS ve RFS’ye 
sahip olarak bulunmuştur. Bu sonuçlar, DNMT3A mutasyonlarının tek 
başına allogenik HKHN yapılan AML hastalarının klinik sonuçlarını 
etkilemediğini işaret etmektedir, ancak FLT3-ITD mutasyonları eşlik 
ettiği zaman, OS’nin önemli ölçüde azaldığı (DNMT3A R882mut/FLT3-
Objective: This study aimed to evaluate DNMT3A exon 23 mutations 
and their prognostic impacts in the presence of NPM1 and FLT3 
mutations in acute myeloid leukemia (AML) patients who underwent 
allogeneic hematopoietic stem cell transplantation (HSCT).
Materials and Methods: This study comprised 128 adult AML patients 
referred to the Hematology-Oncology and Stem Cell Research Center 
of Shariati Hospital. NPM1 and FLT3-ITD mutations were detected by 
fragment analysis. For DNMT3A exon 23 mutation analysis, we used 
Sanger sequencing. Overall survival (OS) and relapse-free survival 
(RFS) curves were estimated by the Kaplan-Meier method and the log-
rank test was used to calculate differences between groups.
Results: The prevalence of DNMT3A exon 23 mutations was 15.6% 
and hotspot region R882 mutations were prominent. RFS and OS were 
compared in patients with and without DNMT3A exon 23 mutations 
using univariate analysis and there was no significant difference 
between these groups of patients. On the contrary, the FLT3-ITD 
mutation significantly reduced the OS (p=0.009) and RFS (p=0.006) 
in AML patients after allogeneic HSCT. In the next step, patients with 
AML were divided into four groups regarding FLT3-ITD and DNMT3A 
mutations. Patients with DNMT3A R882mut/FLT3-ITDpos had the 
worst OS and RFS. These results indicate that DNMT3A mutations 
alone do not affect the clinical outcomes of AML patients undergoing 
allogeneic HSCT, but when accompanied by FLT3-ITD mutations, the 
OS was significantly reduced (5-year OS 0% for DNMT3A R882mut/
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ITD pozitif hastalarda 5 yıllık OS %0 ve DNMT3A R882wt/FLT3-ITD 
negatif hastalarda %62 oranında, p=0,025) ve nüksetme oranının 
arttığı görülmüştür.
Sonuç: AML hastalarında allogeneik HKHN’den sonra bile, DNMT3A 
R882mut/FLT3-ITD pozitifliğinin kötü prognostik faktör olduğu 
sonucuna varılabilir.
Anahtar Sözcükler: Allojenik hematopoetik kök hücre 
transplantasyonu, Akut myeloid lösemi, DNMT3A R882, FLT3-ITD
FLT3-ITDpos patients vs. 62% DNMT3A R882wt/FLT3-ITDneg, p=0.025) 
and the relapse rate increased.
Conclusion: It can be deduced that DNMT3A R882mut/FLT3-ITDpos 
is an unfavorable prognostic factor in AML patients even after 
allogeneic HSCT.
Keywords: Allogeneic hematopoietic stem cell transplantation, Acute 
myeloid leukemia, DNMT3A R882, FLT3-ITD 
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Introduction
Acute myeloid leukemia (AML) is considered a clonal disorder of 
the hematopoietic stem cells marked by proliferation of immature 
myeloid cells in the bone marrow (BM) or peripheral blood. Gene 
fusion, cell signaling abnormalities, and epigenetic modification 
affect the destination of hematopoietic stem cells and could lead to 
leukemogenesis [1,2].
Standard induction chemotherapy, which is a combination of 
cytarabine and anthracyclines, induces a high rate of complete 
remission (CR) in patients with AML; however, the rate of relapse is also 
high. This is more pronounced in elderly patients. Despite this fact, it 
is hoped that the outcome of patients is better when identifying and 
evaluating prognostic factors such as cytogenetics and molecular 
abnormalities [3]. A number of single-gene mutations have served 
for further risk stratification of AML patients. Risk stratification is 
one of the most important applications of molecular abnormalities, 
particularly in determining risk stratification after CR is achieved 
by induction therapy, and it is important because it prevents the 
referral of patients to hematopoietic stem cell transplantation (HSCT) 
centers [4]. As noted above, epigenetic modifications contribute 
to the formation of tumor cells. Epigenetic regulation refers to the 
modification of gene transcription and expression in such a way that 
the genetic code does not change [5].
DNA methylation is one of the most broadly studied mechanisms of 
epigenetic regulation. Methyltransferases are the key enzymes in the 
methylation process. DNMT3A belongs to the DNMTS family, which 
plays a significant role in adding methyl groups to cytosine residues in 
CpG islands. Actively transcribed genes exhibit a nonmethylated CpG 
profile. Cancer genomes are usually seen to have overall decrease in 
5-methylcytosine, although DNA hypermethylation can be seen in 
some areas such as the promoter of tumor suppressor genes [5,6,7]. 
The exact mechanism of the function of DNMT3A mutations in the 
emergence of leukemia is unclear. Possible mechanisms include a 
change in enzyme catalytic properties and impaired binding to its 
ligand. DNMT3A has 23 exons and various mutations have been 
described to date. More than 60% of mutations are localized in the 
R882 hotspot region in the methyltransferase domain. DNMT3A 
mutations are predominantly heterozygous and strongly related to 
FLT3-ITD, IDH-1, and NPM-1 mutations. Differences in the incidence 
of DNMT3A mutations in AML patients were observed to range 
between 4.1% and 25% [8,9,10,11].
BM allogeneic HSCT is the only curative treatment for AML patients 
with intermediate or poor prognosis outcomes. DNMT3A and FLT3-
ITD mutations have been found to be associated with  adverse 
prognosis in patients with AML; however, few studies focused on the 
prognostic impact of these mutations in AML patients treated with 
allogeneic HSCT. The present study assessed the prognostic value of 
DNMT3A R882 and FLT3-ITD mutations in adult AML patients after 
allogeneic HSCT.
Materials and Methods
Patients
From August 2010 to September 2016, a total of 490 AML patients 
were referred to our center. DNA samples of 220 AML patients were 
available. Of those AML patients, 128 treated with allogeneic HSCT 
were enrolled in our study. Of these, 44 were female and 84 were 
male with a median age of 34 years (range: 15-67 years). Approval 
was obtained in writing from all patients in compliance with the 
Declaration of Helsinki and the ethical guidelines of Iran University 
of Medical Sciences.
The patients were diagnosed based on cytomorphology 
using the French-American-British (FAB) classification and 
immunophenotyping, and patients with AML-M3 with molecularly 
confirmed PML/RARA fusion gene were excluded from the study. All 
patients underwent allogeneic HSCT.
The source of hematopoietic stem cells for transplantation was 
peripheral blood, except for one patient who received BM, and donor 
types consisted of matched sibling donors (n=100), matched related 
donors (n=6), matched unrelated donors (n=7), and others (n=15).
Treatment Regimens
The conditioning regimen was non-total body irradiation consisting of 
oral busulfan at 4 mg/kg (days -6 to day -3) and cyclophosphamide at 
60 mg/kg (days -2 and day -1). Antithymocyte globulin (ATG) (r-ATG, 
2.5 mg/kg, Thymoglobulin®, Genzyme) was used  immediately 
before transplantation for 3 (in cases of matched related and 
haploidentical cases) or 2 (in other related cases) days. Graft-versus-
host disease  (GVHD)  prophylaxis consisted of  cyclosporine and 
methotrexate.
Mutation Screenings
DNA was extracted from BM/peripheral blood mononuclear 
cells  according to the  standard salting-out extraction method. 
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DNMT3A exon 23 was amplified by polymerase chain reaction 
(PCR) using forward (5′-GTGTGGTTAGACGGCTTCC-3′) and reverse 
(5′-CTCTCCCACCTTTCCTCTG-3′) primers. Polymerase chain reaction 
cycling conditions were the following: one cycle at 95 °C for 3 min, 
followed by 35 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C 
for 45 s, and then 72 °C for 7 min. Analysis of the PCR products 
was performed by electrophoresis on a 2% agarose gel using the 
BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems). 
The products of PCR were directly sequenced and an automated 
DNA sequencer (Applied Biosystems 3130 Genetic Analyzer) was 
employed. Comparing bidirectional sequence data to a normal 
reference sequence, positive mutations were recognized. Assessment 
of the NPM1 and FLT3-ITD mutations was performed by fragment 
analysis as previously described [12].
Definition of Outcomes
The primary endpoints for survival analysis were overall survival (OS), 
calculated as the duration between the date of transplantation and 
death or last contact; relapse-free survival (RFS), calculated as time 
from the date of transplantation to first relapse; non-relapse mortality 
(NRM), calculated as time from transplantation to death from non-
relapse causes; and cumulative incidence of relapse, defined as the 
time from allogeneic HSCT to the date of hematological relapse and 
considering death in remission as a competitive event. The grading of 
acute and chronic GVHD was based on criteria published previously 
[13].
Statistical Analysis
Comparison  of  clinical characteristics of patients 
for  continuous  variables and  categorical variables was done using 
the Mann-Whitney U test and Pearson’s chi-square test, respectively. 
The Kaplan-Meier method was applied to estimate OS and RFS and 
the log-rank test was used to compare groups. Multivariate Cox 
proportional hazards models were employed to assess OS and RFS. 
The cumulative incidence of NRM and relapse incidence (RI) were 
calculated considering competing risks. Death due to causes other 
than recurrence of disease and relapse were considered as competing 
events for relapse and NRM, respectively. A Fine-Gray proportional 
hazards regression model was used to evaluate the effects of 
covariates on RI and NRM. All variables with a p-value at or below 0.1 
in the univariate analysis were entered in the multivariate analysis. 
Data analysis was performed using SPSS 19 and EZR software [14].
Results 
Mutation Screening
In 20 patients (15.6%), DNMT3A exon 23 mutations were recognized. 
The R882 hotspot region harbors 19 mutations, including c.2645G>A, 
p.(R882H) (n=11); c.2644C>T, p.(R882C) (n=2); and c.2645G>C, p.( 
R882P) (n=6). One patient was found to be heterozygous for a Q905R 
missense mutation (Table 1). All mutations were heterozygous. In 
addition, the G884C synonymous variant was found in 3 patients.
Regarding presenting clinical features, no correlation was found 
between DNMT3A status and median age, sex, hemoglobin, or platelet 
and white blood cell (WBC) counts. Analysis of DNMT3A mutations 
was done with the FAB subtypes of AML. Nine of 20 DNMT3A exon 
23 mutations belonged to M4/M5 of the FAB classification. The 
clinical characteristics and other molecular abnormalities of AML 
patients with mutated or unmutated DNMT3A are presented in Table 
2. The prevalence of FLT3-ITD and NPM1 mutation was 28.1% and 
18.8%, respectively. Among molecular aberrations, NPM1 mutations 
correlated with DNMT3A exon 23 mutations (p=0.014). A statistically 
significant correlation was observed between FLT3-ITD and NPM1 
mutations (p=0.001).
Clinical Outcomes Regarding Molecular Aberration Status after 
Allogeneic HSCT
Analyses of OS and RFS were carried out with a 5-year follow-up 
period. Comparing AML patients with and without DNMT3A exon 
23 mutations, no statistically significant difference was observed 
in OS (p=0.3) or RFS (p=0.29). The 5-year OS estimates were 41% 
in mutated DNMT3A patients versus 56% in AML patients without 
DNMT3A mutations and the 5-year RFS estimates were 41% versus 
57%, respectively (Figure 1).
Analyses of OS and RFS were carried out regarding NPM1 and FLT3-
ITD mutations. NPM1 had no impact on OS (p=0.83) or RFS (P=0.71). 
Regarding RI, a significant difference was observed between AML 
patients with and without NPM1 mutations (p=0.04). AML patients 
with FLT3-ITD mutations had lower OS (p=0.015) and RFS (p=0.012) 
compared to those without FLT3-ITD mutations (Figure 2).
The 5-year RI in the overall population was 30% with significant 
increase in RI regarding FLT3-ITD mutation (p=0.00003). Among 
other risk factors, the CR status at the time of hematopoietic cell 
transplantation was associated with higher RI (p=0.001). The FLT3-
ITD mutation by 3.5-fold and the CR status at allogeneic HSCT by 
2.5-fold triggered an increase in the risk of relapse.
The cumulative incidence of NRM within 5 years was 19.3%. Neither 
DNMT3A exon 23 mutations nor the majority of risk factors were 
found to be in association with NRM. Only in multivariate analysis 
did chronic GVHD increase the risk of NRM by 5.2-fold (p=0.007, 
HR=5.23; 95% CI: 1.66-16.5).
In the next step, AML patients based on DNMT3A and FLT3-ITD 
mutations were divided into four groups: group A (DNMT3A R882wt 
Table 1. Frequency of DNMT3A exon 23 mutations in acute 
myeloid leukemia patients.
Percent Number of patients Type Mutation
8.6% 11 Missense R882H
4.7% 6 Missense R882P
1.5% 2 Missense R882C
0.8% 1 Missense Q905R
2.3% 3 Synonymous G884C
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/FLT3-ITDneg), group B (DNMT3A R882mut /FLT3-ITDpos), group C 
(DNMT3A R882wt/FLT3-ITDpos), and group D (DNMT3A R882mut/
FLT3-ITDneg). Detailed information about these groups is summarized 
in Table 3. WBC counts (p=0.003) and CR status at allogeneic HSCT 
(p=0.022) were statistically significant among groups. Patients with 
DNMT3Awt/FLT3-ITDpos (group C) had the highest WBC counts 
compared with other groups. Considering the CR status (p=0.01) and 
WBC count (p=0.004), the differences were statistically significant 
in the DNMT3Awt/FLT3-ITDpos group (group C) compared with 
DNMT3Awt/FLT3-ITDneg (group A). The cumulative incidence of 
relapse, OS, and RFS rates were compared according to these groups. 
In univariate analysis, the differences in OS and RFS between AML 
patients with coexistence of DNMT3Amut/FLT3-ITDpos (group B) 
and those with DNMT3Awt/FLT3-ITDneg (group A) were statistically 
significant. The DNMT3Amut/FLT3-ITDpos patients (group B) had the 
worst OS (p=0.025) and RFS (p=0.011) compared with other groups, 
revealing a higher RI rate (p=0.0002) (Table 4, Figure 3).
Multivariate Analyses for OS, RFS, and RI 
Multivariate analyses for RFS, OS, and RI were carried out 
regarding the CR condition (CR1 or CR≥2), the interval from CR1 to 
transplantation, FLT3-ITD mutation, DNMT3Amut/FLT3-ITDpos, and 
DNMT3Awt/FLT3-ITDpos. The FLT3-ITD mutation (p=0.03, HR=1.84; 
95% CI: 1.05-3.24) and CR status (p=0.04, HR=1.78; 95% CI: 1.02-
3.13) were independent factors of inferior survival after allogeneic 
HSCT. Regarding RI, CR status to transplantation (p=0.0049, HR= 
2.52; 95% CI: 1.32-4.8) and FLT3-ITD mutation (p=0.00015, HR=3.49; 
95% CI: 1.83-6.68) were significant independent prognostic factors 
for relapse (Table 5).
Figure 2. Survival curves of acute myeloid leukemia patients 
according to mutational status of FLT3-ITD: a) relapse-free 
survival, b) overall survival, c) cumulative incidence of relapse.
Figure 1. Survival curves of acute myeloid leukemia patients 
according to mutational status of DNMT3A: a) relapse-free 
survival, b) overall survival, c) cumulative incidence of relapse.
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Discussion
Although DNMT3A mutations were recognized as driver gene 
mutations in adults with AML, their roles in leukemogenesis remain 
poorly understood. In the past decade, however, DNMT3A mutations 
have been attracting much attention as markers for risk stratification 
in AML patients [15]. 
The present study showed that DNMT3A mutations occur in 15.6% 
(20/128) of AML patients, predominantly in patients with NPM1 
aberrations. The dominant mutation in the study population being 
located at hotspot region R882 is in agreement with previous studies 
[16,17].
The present study finds that DNMT3A R882 mutations are not related 
to inferior survival in AML patients after allogeneic HSCT. It could be 
argued that allogeneic HSCT ameliorates the clinical consequences of 
AML cases with DNMT3A R882 mutations. In the present study, no 
significant difference was found in OS, RFS, or RI between cases with 
DNMT3A mutations and cases with wild-type DNMT3A.
Several studies with controversial results have been conducted on 
the prognostic impact of DNMT3A mutations in AML patients. Some 
studies revealed a statistically significant difference in OS between 
mutated and unmutated DNMT3A patients, with worse OS in the 
mutated cases [16,18,19,20].
Metzeler et al. [21] showed that DNMT3A mutations are on one hand 
related to inferior survival in AML patients and on the other hand 
modify the prognostic effect of mutated NPM1. They also found 
that different types of DNMT3A mutations had no effect on patient 
outcomes. Yuan et al. [22], in a meta-analysis of DNMT3A R882 
mutations in AML patients consisting of eight studies with 4474 AML 
cases with 694 AML patients with DNMT3A R882 mutations, verified 
Table 2. Clinical characteristics of acute myeloid leukemia patients according to DNMT3A status.
Clinical characteristics DNMT3A mutation                    DNMT3A wild-type p-value
Age, years (median ± SD) 
(Minimum - maximum)
39±11
21-57
32±12
16-67  0.1 
Sex
Male
Female
 
12
8
 
 72
 36
 
 0. 4
 
FAB subtypes
M0/M1/M2/M3/M4/M5/M6/M7
 
 0/3/6/0/5/4/2/0
 
3/16/38/1/36/12/2/0 0.75
WBC count at diagnosis
Median
(Minimum - maximum)
 
6200
700-151,000 
 
13,000
 240-257,000 
0.65
PLT count at diagnosis
Median
(Minimum - maximum)
30,500
6000-712,000 
 
61,000
6000-340,000 
 
0.12
Molecular abnormalities
NPM1 wild-type
NPM1 mutation
FLT3-ITDneg
FLT3-ITDpos
 
11
7
13
5
 
 93
 17
79
31
 
 0.014*
 0.28
Interval from CR1 to transplantation, months
Median
(Minimum - maximum)
 
3.1
1-13.4
 
 4.6
 0.3-35.4
 
 
 0.2
Donor type
Matched sibling donor
Others
 
 15
 3
 
 85
 25
 
 
 0.4
Acute GVHD
Yes
No
 
 12
 6
 
 95
 15
 
 
 0.07
Chronic GVHD
Yes
No
 
13
5
 
93
17
 
 
0.19
*p<0.05 is considered significant. 
SD: Standard deviation, CR: complete remission, WBC: white blood cell, PLT: platelet, GVHD: graft-versus-host disease.
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significantly reduced RFS and OS in AML patients with DNMT3A 
R882 mutations.
Focusing on the characteristics and effects of DNMT3A R882 
mutation in AML patients with or without NPM1 and FLT3 mutations, 
Dushyant et al. analyzed 174 AML patients with normal cytogenetics. 
They noticed that DNMT3A mutations in the cytogenetically normal 
AML patients compared to NPM1- and FLT3-mutated patients 
(p=0.067 and p=0.065, respectively) were related to remarkably 
shorter OS and progression-free survival [23].
However, few studies, as mentioned in the following text, have been 
designed to determine the prognostic effect of DNMT3A mutations 
in AML patients treated with allogeneic HSCT.
Consistent with our results, Xu et al. [24] compared the outcomes 
of 55 DNMT3A (mut) patients who underwent allogeneic HSCT (23 
cases) or received chemotherapy (32 cases) for consolidation. They 
observed a significant difference in 3-year OS and DFS between the 
chemotherapy group and the allogeneic HSCT group. The authors 
concluded that DNMT3A mutations act as an unfavorable prognostic 
factor in AML patients with normal cytogenetics and allogeneic HSCT 
improves survival in DNMT3A mutation-positive AML patients. The 
median OS in wild-type DNMT3A patients was greater compared to 
mutated patients but the difference was not statistically significant 
(p=0.151). No significant difference was seen in DFS between these 
groups of patients (p=0.304) [24].
Ahn et al. [25] described DNMT3A R882mut and FLT3-ITDpos as both 
unfavorable prognostic markers for OS and significant risk factors 
for relapse and event-free survival. They declared that patients with 
coexistence of DNMT3A R882 and FLT3-ITD mutations had worse OS, 
worse event-free survival, and higher relapse rates compared with 
other mutations. Indeed, DNMT3A R882mut/FLT3-ITDpos status 
was a significant prognostic marker for poor clinical outcome with 
increasing RI rates even after HSCT.
Tang et al. [26] verified that DNMT3A R882 mutations confer inferior 
survival in AML patients. Their results also indicated that coexistence 
of FLT3-ITD and DNMT3A R882 mutations was an independent factor 
for adverse prognosis after allogeneic HSCT.
Contrary to our results, the findings of Ahn et al. [25] and Tang 
et al. [26] considered DNMT3A R882 as an unfavorable prognostic 
indicator in AML patients treated with allogeneic HSCT. The reason 
for this discrepancy between the results is not clear, but unknown 
cooperating genetic aberrations may be involved. Several studies 
have shown that allogeneic HSCT cannot abrogate the unfavorable 
effect of FLT3-ITD in AML patients [27,28]. Therefore, in the next 
step, we analyzed the surveillance factors of OS, RFS, and RI in FLT3-
ITDpos/DNMT3A R882mut AML patients and encountered the worst 
condition compared with other groups. These results are consistent 
with the findings of the above-mentioned studies [25,26].
Our data also highlighted that CR status prior to transplantation was 
more obvious than other risk factors in delineating risk of relapse. 
In more advanced disease stages (CR2, CR3), more RI occurs. From 
this point of view, our data are in accordance with previous studies 
[29,30].
Study Limitations
The limitations of this research include the following: first, a relatively 
small sample size was used; second, the analysis was limited to exon 
23 of the DNMT3A gene; and third, there is an absence of cytogenetic 
findings. Hence, caution should be taken in the interpretation of the 
results of the present study.
The initial goal of allogeneic HSCT is to improve hematological 
disorders while minimizing residual disease as much as possible. 
To achieve this goal, the patient should be supported through a 
Figure 3. Survival curves of acute myeloid leukemia patients 
according to mutational status of DNMT3A/FLT3-ITD: a) relapse-
free survival, b) overall survival, c) cumulative incidence of relapse.
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conditioning regimen and its associated complications such as GVHD 
while avoiding relapse. ATG can reduce the risk of GVHD, although 
ATG formulation (dose and type), donor type, and other medications 
used for GVHD prophylaxis affect the outcome of allogeneic HSCT 
[31]. In the present study, in order to avoid reducing the number of 
patients, the role of ATG and donor source were ignored.
Allogeneic HSCT is a pragmatic treatment option for relapsed and/
or refractory AML patients; however, it seems that allogeneic HSCT 
cannot override the inferior outcomes conferred by the coexistence 
of DNMT3Amut/FLT3-ITDpos. Our increased knowledge of genetic 
and epigenetic alterations in AML has triggered the emergence of 
new medicines such as CPX-351, FLT3 inhibitors, and epigenetic 
modifiers. Indeed, it is necessary to accompany molecularly targeted 
therapy with allogeneic HSCT for poor prognosis in AML patients.
Table 3. Clinical characteristics of acute myeloid leukemia patients according to DNMT3A R882/FLT3-ITD groups.
Risk factors DNMT3A+/FLT3-ITD+(n=8) DNMT3A-/FLT3-
ITD+(n=29)
DNMT3A+/FLT3-ITD-
(n=12)
DNMT3A-/FLT3-ITD-
(n=79)
p-value
WBC count 11,200 (3100-152,000) 26,000 (2600-226,000) 5400 (700-100,000) 6700 (240-257,000) 0.003
CR 
First CR
≥Second CR
5
3
15
14
11
1
61
18 0.022
Interval from CR1 to 
HSCT, median (months)
>Median
<Median
7
1
12
17
7
5
40
39 0.13
NPM1 mutation
Mutated
Wild-type
3
5
19
10
9
3
73
6 0.008
Acute GVHD
No
Yes
5
3
25
4
8
4
68
11 0.14
Chronic GVHD
No
Yes
6
2
17
12
8
4
65
14 0.3
GVHD: Graft-versus-host disease, HSCT: hematopoietic stem cell transplantation, CR: complete remission.
Table 4. Univariate and multivariate analysis of surveillance factors according to DNMT3A R882/FLT3-ITD groups.
Risk factor status OS RFS
 
Univariate Multivariate Univariate Multivariate
n (%)      Rate at 5 years (%) p-value p-value HR (95% CI)
Rate at 5 
years (%) p-value p-value HR (95% CI)
DNMT3A+/FLT3-ITD+ 8 (6.25) 0 0.025* 0.29 2.68 (1.10-6.94) 0 0.011* 0.18 2.91 (1.20-7.06)
DNMT3A+/FLT3-ITD- 12 (9.4) 57±0.15 0.72 0.71 1.2 (0.46-3.08) 55±0.15 0.76 0.76 1.16 (0.44-2.9)
DNMT3A-/FLT3-ITD+ 29 (22.6) 38±0.11 0.038* 0.36 1.94 (1.03-3.65) 41±0.12 0.037* 0.35 1.97 (1.05-3.7)
DNMT3A-/FLT3-ITD- 79 (61.75) 62±0.6       63±0.6      
Risk factor status RI NRM
  Univariate Univariate
  n (%)             Rate at 5 years (%) p-value Rate at 5 years (%) p-value
DNMT3A+/FLT3-ITD+ 8 (6.25) 81.2 (9.1-98.2) 0.0002* - 0.18
DNMT3A+/FLT3-ITD- 12 (9.4) 8.3 (0.4-32.6) 0.33 36.1 (9.4-64.5) -
DNMT3A-/FLT3-ITD+ 29 (22.6) 52.3 (25.5-73.5) 0.003* 6.9 (1.2-20.1) -
DNMT3A-/FLT3-ITD- 79 (61.75) 21.3 (12.7-31.3) - 22.9 (9.6-39.7) -
*p<0.05 is considered significant.
OS: Overall survival, RFS: relapse-free survival, RI: relapse incidence, NRM: non-relapse mortality, HR: hazard ratio, CI: confidence interval.
165
Ardestani MT, et al: FLT3-ITDpos/DNMT3Amut: Adverse Prognostic Factor in AMLTurk J Hematol 2018;35:158-167
Table 5. Univariate and multivariate analysis of surveillance factors according to risk factor status.
Risk factor status OS RFS
 
Univariate Multivariate Univariate Multivariate
n (%) Rate at 5  years (%) p-value p-value HR (95% CI)
Rate at 5 
years (%) p-value p-value HR (95% CI)
Age, years 
>34 66 (51.6) 53.2±6.9 0.54     53.6±6.8 0.59    
≤34 62 (48.4) 55±6.6       56±6.6      
WBC count     0.52       0.49    
CR 
First CR 92 (71.8) 60.3±5.6 0.011* 0.04 1.78 (1.02-3.13) 60.9±5.5 0.007* 0.027* 1.87 (1.07-3.27)
≥Second CR 36 (28.2) 38.6±8.5       39.7±8.5      
Interval from CR1 to HSCT, median (months) 
>Median 66 (51.6) 61±6.6 0.094* 0.24   62±6.5 0.09    
<Median 62 (48.4) 45.9±6.9       46.7±6.8      
Donor type  
HLA identical sibling 100 (78.1) 55±5.4 0.45     55.9±5.4 0.5    
Others 28 (21.9) 48±10.4       49.8±10.2      
DNMT3A exon 23  
Mutated 20 (15.6) 40±12.2 0.29     40±11.9 0.287    
Wild-type 108 (84.4) 56.7±5       57±5      
FLT3-ITD mutation 
Positive 37 (28.9) 31.6±10.8 0.015* 0.03 1.84 (1.05-3.24) 34±10.9 0.012* 0.022* 1.97 (1.094-3.36)
Negative 91 (71.1) 60.4±5.4       61.1±5.3      
NPM1 mutation
Mutated 24 (18.75) 58±10 0.83     58.3±10 0.71    
Wild-type 104 (81.25) 53±5.4       53.9±5.3      
Acute GVHD
No 22 (17.2) 51.5±5.3 0.4     52.1±5.3 0.37    
Yes 106 (82.8) 68±9.9       68.2±5.4      
Chronic GVHD 0.5                
No 21 (16.4)   0.5     57.1±12.5 0.484    
Yes 92 (83.6)         63.2±5.4      
Risk factor status                 RI NRM
  Univariate Multivariate Univariate Multivariate  
  n (%)       Rate at 5  years (%) p-value p-value HR (95% CI)
Rate at 5 
years (%) p-value p-value HR (95% CI)
Age, years  
≥34 66 (51.6) 33.8 (21.2-46.8) 0.45     13 (6-22) 0.59    
<34 62 (48.4) 28.1 (17.2-40.1)       26 (9-46.7)      
CR 
First CR 92 (71.8) 23.4 (14.6-33.4) 0.001*
0.0049
2.52 (1.32-4.8) 21.7  (10.3-35.7) 0.48    
≥Second CR 36 (28.2) 29.6 (31.5-65.4)       11.8  
(3.6-25.5)
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Conclusion
Based on the findings of the present study, DNMT3A R882 mutations 
seem not to affect the clinical outcomes of AML patients undergoing 
allogeneic HSCT. In contrast, allogeneic HSCT probably improves the 
clinical outcomes of AML patients with DNMT3A R882 mutations. 
When DNMT3A R882 mutations were accompanied by FLT3-ITD 
mutations (DNMT3A R882mut/FLT3-ITDpos), OS was significantly 
reduced, even after allogeneic HSCT. Indeed, FLT3-ITD is a significant 
negative prognostic indicator compared with the DNMT3A R882 
mutation. Further studies are required to better explain a rationale 
for the integration of DNMT3A R882mut/FLT3-ITDpos status in the 
treatment decisions of AML patients.
Acknowledgment
Thanks to the professors and staff of the Hematology-Oncology 
and Stem Cell Transplantation Research Center, Tehran University of 
Medical Sciences.
Ethics 
Ethics Committee Approval: This study was approved by the local 
ethics committee of Iran University of Medical Sciences (approval 
number: 1394.26066).
Informed Consent: Approval consent forms were obtained from all 
patients in compliance with the Declaration of Helsinki.
Authorship Contributions
Surgical and Medical Practices: K.A., A.G., M.V.; Concept: M.T.A., A.K., 
B.C.; Design: M.T.A., S.R., S.M., M.N.; Data Collection or Processing: 
M.T.A., S.R.; Analysis or Interpretation: S.R., M.N., M.J.; Literature 
Search: M.T.A., A.K., B.C.; Writing: M.T.A., A.K., B.C., S.M.
Conflict of Interest: The authors of this paper have no conflicts of 
interest, including specific financial interests, relationships, and/or 
affiliations relevant to the subject matter or materials included.
Table 5. Continued.
Interval from CR1 to HSCT, median (months) 
>Median 66 (51.6) 28.8 (17.4-41.2) 0.53     9.5 (3.8-18.3) 0.76    
<Median 62 (48.4) 33.2 (21.1-45.8)       27.4 (12.9-44.2)      
Donor type  
HLA identical sibling 100 (78.1) 31.7 (22.1-41.7) 0.7     17.6 (8.1-30) 0.2    
Others 28 (21.9) 28.6 (12-47.7)       23.2 (8.8-41.6)      
DNMT3A exon 23  
Mutated 20 (15.6) 29.6 (20.6-39) 0.5     19.3 (8.5-33.4) 0.6    
Wild-type 108 (84.4)
36.9 (15.3-58.8)
      21.9 (6-43.7)      
FLT3-ITD mutation  
Positive 37 (28.9)   0.00003 0.00015* 3.49  (1.83-6.68) 23.8 (12.4-37.2) 0.11    
Negative 91 (71.1)         5.4 (0.9-16.1)      
NPM1 mutation  
Mutated 24 (18.75)   0.04     24.4 (12.2-38.8) 0.02    
Wild-type 104 (81.25)         0      
Acute GVHD             0.7    
No 22 (17.2)   0.12     21.7 (8.5-38.8)      
Yes 106 (82.8)         18.2 (5.5-36.8)      
Chronic GVHD  
No 21 (16.4) 30.7 (20.9-41) 0.12     12.4 (3-28.8) 0.009 0.007* 5.23 (1.66-16.5)
Yes 92 (83.6)         30 (8.9-55)      
*p<0.05 is considered significant.
CR: Complete remission, WBC: white blood cell, GVHD: graft-versus-host disease, OS: overall survival, RFS: relapse-free survival, RI: relapse incidence, NRM: non-relapse mortality, HR: 
hazard ratio, CI: confidence interval.
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